CliniPharma LLC is a private biopharmaceutical company specialized in discovering and developing oral interferon –immunomodulating drugs for high unmet need in asthma and allergy. CliniPharma pipeline consists of two products CP01 and CP02 both are First-in-Class oral controller drugs for the treatment of asthma and allergy under GRANTED patents in the major markets for out-licensing.
CliniPharma was founded by Dr. Nasif in the Middle East in 1993, with the aim of researching the asthma-virus link and we have made the discovery that the anti-virus interferon-a provokes an in vivo influx of eosinophil leucocytes to the airways.
Novel Drug Target
This interferon chemotaxis for eosinophils offers an exiting novel drug target ; a marketed interferon-immunomodulator AM3 was selected for the use in the treatment of asthma and allergy. A series of four proof-of-concept clinical trials were conducted with a positive outcome providing a better and safer drug for the uncontrolled asthma. The unique outcome of the use of AM3 in the treatment of allergic rhinosinusitis is a resolution of the of the mucus membrane thickening in radiologic examination.